Compare UGRO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UGRO | CMND |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 5.3M |
| IPO Year | N/A | N/A |
| Metric | UGRO | CMND |
|---|---|---|
| Price | $0.29 | $1.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 14.0M | 429.1K |
| Earning Date | 02-17-2026 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $59,985,138.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $2.12 |
| 52 Week High | $1.19 | $70.00 |
| Indicator | UGRO | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 61.72 |
| Support Level | $0.32 | $2.40 |
| Resistance Level | $0.38 | $2.88 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 27.86 | 59.49 |
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.